Compare Abeona Therapeutics Inc (ABEO) vs Howmet Aerospace Inc (HWM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Howmet Aerospace Inc — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Howmet Aerospace Inc trades at $270.8 (market cap $110.20B). The key difference: Howmet Aerospace Inc is far larger — about 295.2× Abeona Therapeutics Inc's market cap, and Howmet Aerospace Inc pays a 0.17% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | HWM | |
|---|---|---|
Market Cap | $373.32M | $110.20B |
Sector | Health | Industrials |
52-Week High | $7.23 | $283.23 |
52-Week Low | $4.17 | $171.00 |
Enterprise Value | $228.22M | $112.45B |
Dividend Yield | — | 0.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Howmet Aerospace (HWM) trades at $277.91, up 2.77% today, reflecting strong momentum in the aerospace and defense sectors. The stock exhibits bullish technical signals with support at $273 and resistance at $282. Recent earnings show mixed results, with Q1 2026 missing estimates, but robust profitability metrics like a 20.22% net margin and 33.98% ROE highlight operational strength. Positive sentiment is driven by defense demand and commercial aerospace growth, as noted in Zacks Investment Research articles from July 2026.
Outlook remains positive with an 83% analyst buy rating and a $313.50 consensus price target, suggesting 13% upside. Risks include premium valuations (P/E of 62.74) and execution challenges amid economic uncertainty. The company's cash flow growth and dividend payments support investor confidence, but high multiples warrant caution for new entries.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Howmet Aerospace Inc
Howmet Aerospace provides advanced engineered solutions for the aerospace and transportation industries. It specializes in jet engine components, aerospace fastening systems, and forged aluminum wheels.
Read more on HWM →
